Log in

Relevant bibliographies by topics / Lymphocyte therapy / Journal articles

To see the other types of publications on this topic, follow the link: Lymphocyte therapy.

Journal articles on the topic 'Lymphocyte therapy'

Author: Grafiati

Published: 2 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Lymphocyte therapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Silverman, David A., and Dennis J. Chapron. "Lymphopenic Effect of Carbamazepine in a Patient with Chronic Lymphocytic Leukemia." Annals of Pharmacotherapy 29, no. 9 (1995): 865–67. http://dx.doi.org/10.1177/106002809502900906.

Full text

Abstract:

Objective: To report a dramatic and reproducible suppressive effect of carbamazepine on circulating lymphocytes in an elderly woman with chronic lymphocytic leukemia. Case Summary: An elderly woman taking phenytoin for a stroke-associated seizure disorder had lymphocyte count of 28 800 × 106 cells/L. Speculating an unusual lymphadenopathic effect of the phenytoin therapy, carbamazepine therapy was substituted. After 15 weeks of carbamazepine treatment, the lymphocyte count declined to 3200 × 106 cells/L. Because of severe diarrhea, carbamazepine therapy was stopped and phenytoin therapy was re

APA, Harvard, Vancouver, ISO, and other styles

2

Broughan, Thomas A., Rafael Valenzuela, Eduardo Escorcia, Michelle Secic, and David P. Vogt. "Mouse antibody‐coated lymphocytes during OKT3 therapy in liver transplantation." Clinical Transplantation 8, no. 5 (1994): 488–91. http://dx.doi.org/10.1111/j.1399-0012.1994.tb00275.x.

Full text

Abstract:

Flow cytometry has been a technique in search of a use in transplantation. With each new monoclonal antibody, it has been hoped that the secrets of rejection would be unlocked. The usefulness of CD3+ T‐ lymphocyte counts to predict successful treatment of organ transplant rejection has been called into question. CD2+, CD3+, and mouse antibody‐coated CD3 lymphocytes were followed by flow cytometry in 44 liver transplant patients during OKT3 therapy for induction or rejection. CD3+ lymphocyte counts did not predict successful management of rejection by OKT3. When expressed as percentages of the

APA, Harvard, Vancouver, ISO, and other styles

3

Gokce, Aksanur, Tulay Omma, Mustafa Çelikc, and Işılay Taşkaldıran. "An overview of the hematological picture with antithyroid therapy in Graves' disease." Acta Facultatis Medicae Naissensis 39, no. 4 (2022): 467–75. http://dx.doi.org/10.5937/afmnai39-36192.

Full text

Abstract:

Aim: Graves' disease is an autoimmune thyroid disease that is the most common cause of hyperthyroidism. Peripheral blood cell parameters such as neutrophils, lymphocytes, and platelets play a role in inflammation control. Several studies have proven that neutrophil-lymphocyte ratio, monocyte-lymphocyte ratio and platelet-lymphocyte ratio are indicators of chronic subclinical inflammation in various diseases. In our study, we aimed to review the peripheral blood picture by evaluating these parameters before and after antithyroid treatment in patients with Graves' disease. Patients and methods:

APA, Harvard, Vancouver, ISO, and other styles

4

Culver, Kenneth W., W. French Anderson, and R. Michael Blaese. "Lymphocyte Gene Therapy." Human Gene Therapy 2, no. 2 (1991): 107–9. http://dx.doi.org/10.1089/hum.1991.2.2-107.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Prabowo, Rangsang Bagus, Dewi Indah Noviana Pertiwi, and FX Hendriyono. "CD4 LYMPHOCYTE IN HIV / AIDS BEFORE AND AFTER ANTIRETROVIRAL THERAPY." Berkala Kedokteran 13, no. 2 (2017): 183. http://dx.doi.org/10.20527/jbk.v13i2.4074.

Full text

Abstract:

Abstract: Human Immunodefficiency Virus (HIV) is a virus that decreases the human immunity system, therefore the infected people become susceptible to any kind of infections. Examination of CD4 lymphocyte count periodically is one of the antiretroviral therapy success indicators. The purpose of this research was to determine the difference of CD4 lymphocyte count before and after antiretroviral therapy at Ulin General Hospital Banjarmasin on 2013-2015. The method of this research was observational analytic with cross-sectional approach. The study population was 55 patients which were selected

APA, Harvard, Vancouver, ISO, and other styles

6

Lissoni, Paolo, Sandro Barni, Marco Andres, et al. "Lymphocytosis Decline is not Responsible for Tumor Progression in Cancer Patients Chronically Treated with Interleukin-2." Tumori Journal 80, no. 4 (1994): 283–85. http://dx.doi.org/10.1177/030089169408000408.

Full text

Abstract:

Aims and background The antitumor activity of IL-2 is mediated by an increase in lymphocyte number. Moreover, our previous studies have shown that therapy for 1 week/month with low-dose subcutaneous IL-2 is sufficient to maintain high levels of lymphocytes in cancer patient who have had tumor regression or stable disease (SD) in response to IL-2 immunotherapeutic cycles. This study was performed to establish whether tumor progression in cancer patients chronically treated with IL-2 may be associated with lymphocyte number decline. Methods The study included 53 metastatic renal cell cancer pati

APA, Harvard, Vancouver, ISO, and other styles

7

Zeremski, Vanja, Aleksandar Savic, Vesna Cemerikic-Martinovic, Ivana Milosevic, Marina Dragicevic, and Farra El. "The case of T-cell large granular lyphocyte leukemia presented as transfusion dependent anemia with sustained response to cyclosporine a therapy: Case report." Medical review 69, no. 11-12 (2016): 376–78. http://dx.doi.org/10.2298/mpns1612376z.

Full text

Abstract:

Case report. A 41-year-old man presented with anemia, lymphocytosis and splenomegaly. T-cell large granular lymphocyte leukemia was diagnosed based on lymphocytosis of T-cell large granular lymphocytes, characteristic immunophenotype (CD3+, CD8+, CD16+, CD57+) of the lymphocytes and clonally rearranged T-cell receptor genes. Therapy indication was transfusion-dependent anemia. Initial cyclosporine therapy and low-dose oral methotrexate failed to control anemia and lymphocytosis. Yet, a complete clinical and hematological response (without molecular remission) was achieved and sustained when cy

APA, Harvard, Vancouver, ISO, and other styles

8

Francis, G., L. Kappos, P. O’Connor, et al. "Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy." Multiple Sclerosis Journal 20, no. 4 (2013): 471–80. http://dx.doi.org/10.1177/1352458513500551.

Full text

Abstract:

Background: Reduction in peripheral blood lymphocytes is an expected pharmacodynamic outcome of fingolimod therapy. Objective: The objective of this article is to evaluate lymphocyte dynamics during and after fingolimod therapy and assess the relationship between lymphocyte counts and infections. Methods: Lymphocyte counts and their relationship with infections were evaluated in three multiple sclerosis (MS) populations: (Group A) FREEDOMS phase 3 core study group ( n = 1272); (Group B) All Studies group (one phase 2 and two phase 3 studies, plus their extensions; n = 2315); and (Group C) Foll

APA, Harvard, Vancouver, ISO, and other styles

9

Chen, Yang, Yanyan Xie, Min Ruan та Jinning Shi. "The Levels of T Lymphocyte Subsets in Immune Thrombocytopenia Associated with Anti-GPIIb/IIIa- and/or Anti-GPIbα-Mediated Responses Are Differentially Sensitive to Dexamethasone". Acta Haematologica 140, № 1 (2018): 60–66. http://dx.doi.org/10.1159/000491977.

Full text

Abstract:

Objective: The aim of this work was to investigate the influence of T lymphocyte subsets and platelet-specific autoantibodies on immune thrombocytopenia (ITP) with dexamethasone therapy. Methods: The samples were obtained from patients before therapy. T lymphocyte subsets were measured by flow cytometry, and platelet-specific autoantibodies were evaluated by modified monoclonal antibody immobilization of platelet antigen assay. Results: A total of 50 ITP patients were involved in the study. Twenty-three were anti-GPIbα antibody positive and were treated with dexamethasone, with a response rate

APA, Harvard, Vancouver, ISO, and other styles

10

von Roemeling, Christina, Jeet Patel, Savannah Carpenter, et al. "EXTH-48. ADENO-ASSOCIATED VIRUS TARGETING OF THE TUMOR MICROENVIRONMENT TO IMPROVE LYMPHOCYTE RECRUITMENT IN GLIOBLASTOMA." Neuro-Oncology 26, Supplement_8 (2024): viii247—viii248. http://dx.doi.org/10.1093/neuonc/noae165.0979.

Full text

Abstract:

Abstract BACKGROUND Glioblastoma (GBM) is notoriously devoid of lymphocytes driven in part by a paucity of lymphocyte trafficking factors necessary to prompt their recruitment, infiltration, and activation. We have developed a novel recombinant adeno-associated virus (AAV) gene therapy strategy that enables focal and stable reconstitution of the GBM tumor microenvironment (TME) with C-X-C motif ligand 9 (CXCL9), a powerful call-and-receive chemokine for cytotoxic T lymphocytes (CTLs). By increasing lymphocyte recruitment in GBM, we HYPOTHESIZE that these tumors will be more responsive to immun

APA, Harvard, Vancouver, ISO, and other styles

11

Roush, Karen S., and Christopher D. Hillyer. "Donor lymphocyte infusion therapy." Transfusion Medicine Reviews 16, no. 2 (2002): 161–76. http://dx.doi.org/10.1053/tmrv.2002.31464.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Radvanyi, Laszlo G. "Tumor-Infiltrating Lymphocyte Therapy." Cancer Journal 21, no. 6 (2015): 450–64. http://dx.doi.org/10.1097/ppo.0000000000000162.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Skurikhin, Evgenii G., Olga Pershina, Natalia Ermakova, et al. "Reprogrammed CD8+ T-Lymphocytes Isolated from Bone Marrow Have Anticancer Potential in Lung Cancer." Biomedicines 10, no. 6 (2022): 1450. http://dx.doi.org/10.3390/biomedicines10061450.

Full text

Abstract:

CD8+ T-lymphocytes play a key role in antitumor immune response. Patients with lung cancer often suffer from T-lymphocyte dysfunction and low T-cell counts. The exhaustion of effector T-lymphocytes largely limits the effectiveness of therapy. In this study, reprogrammed T-lymphocytes used MEK inhibitors and PD-1 blockers to increase their antitumor activity. Antitumor effects of reprogrammed T-lymphocytes were shown in vitro and in vivo in the Lewis lung carcinoma model. The population of T- lymphocytes with persistent expression of CCR7 was formed as a result of reprogramming. Reprogrammed T-

APA, Harvard, Vancouver, ISO, and other styles

14

Komakh, Yu A., S. A. Borzenok, S. V. Petrichuk, D. G. Kuptsova, and T. V. Radigina. "Metabolic therapy of predicted complications in immunocompromised recipients before repeated corneal transplantation." Russian Journal of Immunology 24, no. 4 (2021): 495–500. http://dx.doi.org/10.46235/1028-7221-1076-mto.

Full text

Abstract:

One of the topical problems of modern ophthalmotransplantology is the graft engraftment after repeated keratoplasty. During repeated corneal transplantation, the frequency of graft rejection increases significantly. The study included 121 patients aged 19 to 89 years with corneal graft failure, who were scheduled for repeated corneal transplantation. Immunophenotyping of major and small populations of peripheral blood lymphocytes was performed by flow cytometry (CytoFlex BC, USA). The intensity of energy metabolism in lymphocyte populations was determined by the activity of succinate dehydroge

APA, Harvard, Vancouver, ISO, and other styles

15

Scalia, Giulia, Maddalena Raia, Monica Gelzo, et al. "Lymphocyte Population Changes at Two Time Points during the Acute Period of COVID-19 Infection." Journal of Clinical Medicine 11, no. 15 (2022): 4306. http://dx.doi.org/10.3390/jcm11154306.

Full text

Abstract:

We previously observed an increase of serum interleukins (IL) and a reduction of most lymphocyte subpopulations in hospitalized COVID-19 patients. Herein, we aimed to evaluate the changes in serum IL-6, IL-10, and IL-17A levels and cytometric lymphocyte profiles in 144 COVID-19 patients at admission and after one week, also in relation to steroid treatment before hospitalization. After one week of hospitalization, we found that: (i) total lymphocytes were increased in all patients; (ii) neutrophils and IL-6 were reduced in mild/moderate patients; (iii) B lymphocytes were increased in severe pa

APA, Harvard, Vancouver, ISO, and other styles

16

Mustjoki, Satu, and Kimmo Porkka. "Appearance of Bone Marrow Lymphocytosis as a Sign of Immunoactivation Is Associated with a Good Response to Imatinib Therapy in Patients with Chronic Myeloid Leukemia." Blood 108, no. 11 (2006): 4775. http://dx.doi.org/10.1182/blood.v108.11.4775.4775.

Full text

Abstract:

Abstract In addition to potent BCR-ABL -mediated anti-leukemia effects, growing evidence suggests that imatinib mesylate (IM) also acts as an immunomodulatory agent. IM modulates both innate and adaptive immunity with impact on dendritic, NK, and T cell activation. Current data implies an immunostimulatory effect of IM, which could be a factor in the long-term control of chronic myeloid leukemia (CML). Modest increase in BM lymphocyte count has often been observed during imatinib therapy. We speculated that this increase may be related to the immunoactivation induced by IM and studied the rela

APA, Harvard, Vancouver, ISO, and other styles

17

Suzuki, Takeshi, Kei Inoue, Toru Igarashi, et al. "Beta-Blocker Therapy Preserves Normal Splenic T-Lymphocyte Numbers Reduced in Proportion to Sepsis Severity in a Sepsis Model." Critical Care Research and Practice 2019 (December 11, 2019): 1–5. http://dx.doi.org/10.1155/2019/8157482.

Full text

Abstract:

Lymphocyte cell death contributes to sepsis-induced immunosuppression, leading to poor prognosis. This study examined whether sepsis severity and beta-blocker therapy could affect the degree of T-lymphocyte cell death in a mouse model of sepsis. In the first control study, 20 animals were allocated to 4 groups: control group with sham operation (group C, n = 5) and 3 groups with cecum ligation and puncture (CLP) performed at 3 different sites: proximal, middle, and distal cecum (groups CLP-P, CLP-M, and CLP-D, respectively; n = 5 in each group). Their spleens were resected under general anesth

APA, Harvard, Vancouver, ISO, and other styles

18

Stein, D. S., and G. L. Drusano. "Modeling of the change in CD4 lymphocyte counts in patients before and after administration of the human immunodeficiency virus protease inhibitor indinavir." Antimicrobial Agents and Chemotherapy 41, no. 2 (1997): 449–53. http://dx.doi.org/10.1128/aac.41.2.449.

Full text

Abstract:

We investigated the relationships between changes in CD4 lymphocytes counts over 24 weeks after the initiation of therapy with indinavir at dosages of > or = 2.4 g/day (n = 15) in human immunodeficiency virus-positive patients and compared them to the baseline values. Starting CD4 count were linked to the time-weighted average CD4 cell count (return) through a nonlinear effect model. The diminution of destruction of CD4 cells after the initiation of indinavir therapy was estimated by fitting simultaneous differential equations to the data by using a linked lymph node (LN)-blood (BL) (two-co

APA, Harvard, Vancouver, ISO, and other styles

19

Baidina, T. V., E. M. Kuklina, N. V. Selyanina, et al. "STUDY OF MULTIPLE SCLEROSIS PATHOGENESIS AS THE BASIS OF ITS TARGET THERAPY." Perm Medical Journal 35, no. 1 (2018): 27–32. http://dx.doi.org/10.17816/pmj35127-32.

Full text

Abstract:

Aim. To study the antigen-presenting ability of B-cells, class IV semaphorin Sema4D (CD100) and CD72 receptor expression in the immune system of patients with multiple sclerosis (MS); to study the interaction between the KIF1B gene polymorphisms and the variants of response to preparation, changing the course of multiple sclerosis in MS patients. Materials and methods. Patients with the established diagnosis of “Multiple sclerosis” by McDonald criteria 2010 with remitting type of the disease course were examined. Clinical method, psychometric testing, immune-enzyme analysis, immunologic method

APA, Harvard, Vancouver, ISO, and other styles

20

Cianci, Rossella, Maria Grazia Massaro, Elisabetta De Santis, et al. "Changes in Lymphocyte Subpopulations after Remdesivir Therapy for COVID-19: A Brief Report." International Journal of Molecular Sciences 24, no. 19 (2023): 14973. http://dx.doi.org/10.3390/ijms241914973.

Full text

Abstract:

Remdesivir (RDV) has demonstrated clinical benefit in hospitalized COronaVIrus Disease (COVID)-19 patients. The objective of this brief report was to assess a possible correlation between RDV therapy and the variation in lymphocyte subpopulations. We retrospectively studied 43 hospitalized COVID-19 patients: 30 men and 13 women (mean age 69.3 ± 15 years); 9/43 had received RDV therapy. Six patients had no need for oxygen (severity group 0); 22 were on oxygen treatment with a fraction of inspired oxygen (FiO2) ≤ 50% (group 1); 7 on not-invasive ventilation (group 2); 3 on invasive mechanical ve

APA, Harvard, Vancouver, ISO, and other styles

21

Renner, Lorna, Meghan Prin, Fang-Yong Li, Bamenla Goka, Veronika Northrup, and Elijah Paintsil. "Time to and Predictors of CD4+ T-Lymphocytes Recovery in HIV-Infected Children Initiating Highly Active Antiretroviral Therapy in Ghana." AIDS Research and Treatment 2011 (2011): 1–9. http://dx.doi.org/10.1155/2011/896040.

Full text

Abstract:

Background. CD4+ T-lymphocyte monitoring is not routinely available in most resource-limited settings. We investigated predictors of time to CD4+ T-lymphocyte recovery in HIV-infected children on highly active antiretroviral (HAART) at Korle-Bu Teaching Hospital, Ghana.Methods. Time to CD4+ T-lymphocyte recovery was defined as achieving percent CD4+ T-lymphocytes of 25%. We used Cox proportional hazard models for identifying significant predictor variables.Results. Of the 233 children with complete CD4+ T-lymphocyte data, the mean age at HAART initiation was 5.5 (SD=3.1) years. The median reco

APA, Harvard, Vancouver, ISO, and other styles

22

Waldmann, Herman, and Geoff Hale. "CAMPATH: from concept to clinic." Philosophical Transactions of the Royal Society B: Biological Sciences 360, no. 1461 (2005): 1707–11. http://dx.doi.org/10.1098/rstb.2005.1702.

Full text

Abstract:

Lymphocyte depletion has a long history in the area of therapeutic immunosuppression. CAMPATH-1H (alemtuzumab) was generated in an attempt to replace anti-lymphocyte globulins in the transplant arena. Its efficacy in killing lymphocytes has established it as a licensed drug for the management of chronic lymphocyte leukaemia. Short-term therapy with alemtuzumab has demonstrated long-term benefit in a number of autoimmune conditions. This drug has the potential to facilitate recruitment of tolerance processes so enabling drug minimization in transplantation, autoimmune and hypersensitivity disea

APA, Harvard, Vancouver, ISO, and other styles

23

Maslak, G. S., G. P. Chernenko, S. V. Abramov, et al. "Glycobiom Lymphocytes Surface Study of Patients with B-Cell Chronic Lymphocytic Leukemia." Ukraïnsʹkij žurnal medicini, bìologìï ta sportu 6, no. 6 (2021): 134–40. http://dx.doi.org/10.26693/jmbs06.06.134.

Full text

Abstract:

The purpose of the study was to investigate the intensity of exposure of peripheral blood lymphocyte surface glycans in patients with B-cell chronic lymphocytic leukemia by measuring the density of lectin- or antigen-positive epitopes under antitumor therapy in order to evaluate it for a more reasonable selection of qualitative and quantitative composition of therapy. Materials and methods. The objects of the study were blood lymphocytes of patients with chronic lymphocytic leukemia (n=15) aged 58-66 years before and after a course of standard chemotherapy according to the COP scheme. The cont

APA, Harvard, Vancouver, ISO, and other styles

24

Weissenbacher, Annemarie, Theresa Hautz, Michael Kimelman, et al. "Lymphocytes as an Indicator for Initial Kidney Function: A Single Center Analysis of Outcome after Alemtuzumab or Basiliximab Induction." Journal of Immunology Research 2015 (2015): 1–6. http://dx.doi.org/10.1155/2015/985460.

Full text

Abstract:

Alemtuzumab, an anti-CD52 T-cell and B-cell depleting monoclonal antibody, is established for induction therapy in renal transplantation (KTx). We herein provide a comparative analysis between alemtuzumab and basiliximab induction therapy and correlate lymphocyte depletion and recovery with the clinical course after KTx. This is a single center retrospective analysis of 225 patients/consecutive kidney transplantations treated with alemtuzumab for lymphocyte depletion and 205 recipients treated with basiliximab. Mean lymphocyte counts were 22.8 ± 9.41% before Tx and 2.61 ± 3.11% between week 1

APA, Harvard, Vancouver, ISO, and other styles

25

Baron, Beverly W., Michael J. Thirman, Mihai C. Giurcanu, and Joseph M. Baron. "Quercetin Therapy for Selected Patients with PIM1 Kinase-Positive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Pilot Study." Acta Haematologica 139, no. 2 (2018): 132–39. http://dx.doi.org/10.1159/000486361.

Full text

Abstract:

We reported that PIM1 kinase is expressed in the lymphocytes of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Quercetin, a naturally occurring flavonoid, is a dietary supplement and inhibits many kinases, including PIM1, in vitro. Under an Institutional Review Board-approved protocol, we performed an open-label, single-arm pilot study to evaluate the antitumor activity of quercetin in patients with CLL/SLL. Q-ForceTM chews were administered orally, 500 mg twice daily, for 3 months. Eligible patients had failed prior therapies, had had no other standard trea

APA, Harvard, Vancouver, ISO, and other styles

26

Peggs, Karl S., and Stephen Mackinnon. "Cellular therapy: donor lymphocyte infusion." Current Opinion in Hematology 8, no. 6 (2001): 349–54. http://dx.doi.org/10.1097/00062752-200111000-00006.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Vrndic, Olgica B., Predrag M. Djurdjevic, Danijela D. Jovanovic, et al. "Blood cells in thyroid cancer patients: a possible influence of apoptosis." Open Medicine 11, no. 1 (2016): 87–92. http://dx.doi.org/10.1515/med-2016-0017.

Full text

Abstract:

AbstractThe side effects of radioactive iodine (131-I) treatment of differentiated thyroid cancer (DTC) patients include reduction of peripheral blood cell counts. The aim of this study was to analyze some potential changes in blood cell counts of DTC patients after 131-I therapy, especially CD3-positive, CD19-positive, and CD56-positive peripheral blood lymphocytes (PBL), as well as the possible role of apoptosis in selected lymphocyte populations. The study group included 24 thyroid cancer patients and 24 control subjects. Peripheral blood samples from patients and controls were analyzed usi

APA, Harvard, Vancouver, ISO, and other styles

28

El Missiry, Mohamed, Shady Adnan, Hanna Rajala, et al. "Bone Marrow Lymphocytic Status during Tyrosine Kinase Inhibitor Therapy and Its Relation to Therapy Response in Chronic Phase Chronic Myeloid Leukemia Patients." Blood 126, no. 23 (2015): 4027. http://dx.doi.org/10.1182/blood.v126.23.4027.4027.

Full text

Abstract:

Abstract Introduction The introduction of tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of chronic myeloid leukemia (CML). In addition to blocking their main target kinase, the BCR-ABL oncoprotein, several studies have reported that TKIs could also have secondary effects on the immune system and lymphocyte behavior. The aim of this study was to assess the bone marrow (BM) lymphocyte status at diagnosis and during different first-line TKI therapies and correlate it with treatment responses. Methods Altogether 105 first-line TKI treated patients were included in the study (i

APA, Harvard, Vancouver, ISO, and other styles

29

Oldstone, M. B. "Viruses as therapeutic agents. I. Treatment of nonobese insulin-dependent diabetes mice with virus prevents insulin-dependent diabetes mellitus while maintaining general immune competence." Journal of Experimental Medicine 171, no. 6 (1990): 2077–89. http://dx.doi.org/10.1084/jem.171.6.2077.

Full text

Abstract:

A situation in which virus can be used as a therapeutic agent to prevent a lethal autoimmune disease is explored. Nonobese insulin-dependent diabetes (NOD) mice spontaneously develop insulin-dependent diabetes mellitus (IDDM), characterized by lymphocytic infiltration into the islets of Langerhans and beta cell destruction, resulting in hypoinsulinemia, hyperglycemia, ketoacidosis, and death. Infection of NOD mice with lymphocytic choriomeningitis virus (LCMV) aborts the autoimmune manifestations and resultant IDDM. The viruses' effect is on a subset of CD4+ lymphocytes. Ablating this autoimmu

APA, Harvard, Vancouver, ISO, and other styles

30

Paolo, Lissoni, Porro Giorgio, Cenaj Vezika, Aymerich Tiziana, Lissoni Arianna, and Di Fede Giuseppe. "A Phase-2 Study on the Kinetics of the Improvement in Lymphocyte-toMonocyte Ratio by High-Dose Pineal Hormone Melatonin in Lymphocytopenic Untreatable Metastatic Cancer Patients." Cancer Medicine Journal 2, no. 1 (2019): 14–19. http://dx.doi.org/10.46619/cmj.2019.2-1008.

Full text

Abstract:

It is known that lymphocytopenia is one of the most negative biomarkers in cancer patients, being an expression of cancer-related immunosuppression. Today it is known that, despite its complexity, the antitumor immunity is mainly mediated by dendritic cell-T lymphocyte system and suppressed by the macrophage-regulatory T lymphocyte system. Then, lymphocyte-to-monocyte ratio (LMR) has been proven to represent a more appropriate prognostic clinical index than the simple lyphocytopenia alone. Because of the fundamental role of lymphocytes in mediating tumor cell destruction, the correction of can

APA, Harvard, Vancouver, ISO, and other styles

31

Aulia, Nabiella Hasti, Hadi Irawiraman, and Eva Susanti. "Hubungan antara Rasio Neutrofil Terhadap Limfosit Preterapi dengan Angka Harapan Hidup Pasien Karsinoma Nasofaring di RSUD Abdoel Wahab Sjahranie Tahun 2018." Jurnal Kesehatan Andalas 12, no. 1 (2023): 27. http://dx.doi.org/10.25077/jka.v12i1.2155.

Full text

Abstract:

Nasopharyngeal carcinoma is a malignancy that originates from the epithelial tissues lining the nasopharynx and is considered one of the most common malignant cancers which cause mortality in Indonesia. Neutrophils and lymphocytes are the first lines to provide body immunity against foreign substances. Neutrophil-to-Lymphocyte Ratio (NLR) is a prognostic factor in various malignancies. Objective: To investigated the correlation between pre-therapy Neutrophil-to-Lymphocyte Ratio (NLR) and survival rate among patients with nasopharyngeal carcinoma at Abdoel Wahab Sjahranie Regional Public Hospit

APA, Harvard, Vancouver, ISO, and other styles

32

Rodionova, T. I., M. Yu Ledvanov, and V. V. Firstova. "Electrokinetic potential of blood lymphocytes in autoimmune ophthalmopathy in patients with diffuse toxic goiter." Problems of Endocrinology 44, no. 3 (1998): 12–15. http://dx.doi.org/10.14341/probl199844312-15.

Full text

Abstract:

Electrophoretic mobility (ЕРМ) of blood lymphocytes was studied in 103 patients with diffuse toxic goiter (DTG) and autoimmune ophthalmopathy (AO) and 30 healthy controls in order to assess the value of this parameter as a criterion of AO severity and assessment of the efficacy of therapy of AO. The patients were in a state of drug-induced euthyrosis. A О was treated traditionally (nonsteroid antiinflammatory drugs, glucocorticoids, and glucocorticoids combined with radiotherapy of the orbits), depending on the severity of the condition. The distribution of blood lymphocytes by EPM is notably

APA, Harvard, Vancouver, ISO, and other styles

33

Farina, Mirko, Marco Chiarini, Camillo Almici, et al. "Timely Leukapheresis May Interfere with the “Fitness” of Lymphocytes Collected for CAR-T Treatment in High Risk DLBCL Patients." Cancers 14, no. 21 (2022): 5276. http://dx.doi.org/10.3390/cancers14215276.

Full text

Abstract:

The development of chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of hematological diseases. However, approximately 60% of patients relapse after CAR-T cell therapy, and no clear cause for this failure has been identified. The objective of the Bio-CAR-T BS study (ClinicalTrials.gov: NCT05366569) is to improve our understanding of the lymphocyte harvest to maximize the quality of the CAR-T cell product. Of the 14 patients enrolled, 11 were diagnosed with DLBCL, 2 with PMBCL, and 1 with ALL. Five of 11 DLBCL patients met the criteria for “pre-emptive” Lymphocytes

APA, Harvard, Vancouver, ISO, and other styles

34

Araujo, Alessandra, Max Rodnick-Smith, Ranya Al-Khaledy, Mark Badeaux, and Everett Stone. "Abstract 4884: Reversing immune desertification for effective cancer therapy." Cancer Research 85, no. 8_Supplement_1 (2025): 4884. https://doi.org/10.1158/1538-7445.am2025-4884.

Full text

Abstract:

Abstract Patients with tumors that have a “cold, or “immune desert” phenotype typically have poor outcomes on immune checkpoint therapy (ICT). Aberrant sphingosine-1-phosphate (S1P) signaling in tumors and in their draining lymph nodes (TDLN) appears to causes a common form of immune desertification by disabling or stalling lymphocyte egress from the TDLN, ultimately restricting immune trafficking to tumors. Clinically, tumor expression levels of the S1P producing enzyme sphingosine kinase 1 (SPHK1) strongly and negatively correlate with survival of patients after immune checkpoint inhibitor (

APA, Harvard, Vancouver, ISO, and other styles

35

PRICE, David A., Chris A. O'CALLAGHAN, Joseph A. WHELAN, Philippa J. EASTERBROOK, and Rodney E. PHILLIPS. "Cytotoxic T lymphocytes and viral evolution in primary HIV-1 infection*." Clinical Science 97, no. 6 (1999): 707–18. http://dx.doi.org/10.1042/cs0970707.

Full text

Abstract:

Efforts to develop immune-based therapies for HIV infection have been impeded by incomplete definition of the immunological correlates of protection. Despite many precedents demonstrating that CD8+ cytotoxic T lymphocytes are key mediators of protective anti-viral immunity in non-human animal models, direct evidence that these effector cells control viral replication in HIV-1 infection has remained elusive. The first part of this paper describes a detailed immunological and genetic study founded on evolutionary considerations. Following infection with HIV-1, virus variants which escaped recogn

APA, Harvard, Vancouver, ISO, and other styles

36

Kreutzman, Anna, Vesa Juvonen, Veli Kairisto, et al. "Mono/Oligoclonal T and NK Cells Are Common in Philadelphia Chromosome Positive (Ph+) Leukemia Patients at Diagnosis and Expand During Successful Tyrosine Kinase Inhibitor Therapy." Blood 114, no. 22 (2009): 856. http://dx.doi.org/10.1182/blood.v114.22.856.856.

Full text

Abstract:

Abstract Abstract 856 Introduction. Central to current treatment of Ph+ leukemia patients are tyrosine kinase inhibitors (TKIs), which predominantly target the BCR-ABL1 kinase in malignant cells. However, broader-spectrum 2nd generation TKIs, such as bosutinib, dasatinib and nilotinib, also inhibit off-target kinases with important physiological functions. Several in vitro studies have implied that TKIs may have immunosuppressive effects by suppressing activation and proliferation of effector lymphocytes. In contrast, we recently observed immunostimulation during dasatinib therapy in the form

APA, Harvard, Vancouver, ISO, and other styles

37

Belova, Yuliana A., Yulia Yu Chuksina, Sergey V. Kotov, and Irina A. Vasilenko. "Cell-Mediated Immunity in Multiple Sclerosis Patients Who Discontinued Therapy with an Integrin Inhibitor." Annals of Clinical and Experimental Neurology 18, no. 1 (2024): 12–19. http://dx.doi.org/10.54101/acen.2024.1.2.

Full text

Abstract:

Introduction. Natalizumab (NTZ) is a humanized monoclonal antibody (mAb) that selectively inhibits α4-integrin adhesion molecule located on the surface of lymphocytes and prevents their trafficking into the central nervous system (CNS). The aim of this study was to identify characteristics of lymphocyte population and subpopulation pattern in the peripheral blood (PB) of multiple sclerosis (MS) patients who discontinued NTZ due to an increased risk of developing developing progressive multifocal leukoencephalopathy. Materials and methods. We conducted an open-label prospective obse

APA, Harvard, Vancouver, ISO, and other styles

38

Saito, Toshiki I., Marie T. Rubio, and Megan Sykes. "Clinical Relevance of Recipient Leukocyte Infusion (RLI) Therapy." Blood 104, no. 11 (2004): 2120. http://dx.doi.org/10.1182/blood.v104.11.2120.2120.

Full text

Abstract:

Abstract BACKGROUND Surprisingly, anti-tumor responses can occur in patients who reject donor grafts following nonmyeloablative hematopoietic cell transplantation (Dey et al., Biol Blood Marrow Transplant 7:604). In murine mixed chimeras prepared with nonmyeloablative conditioning, we previously showed that recipient leukocyte infusions (RLI) induced anti-tumor responses against host-type tumors (Rubio et al. Blood 102:2300). To further investigate the clinical relevance of this RLI model, we: Evaluated the effect of RLI from tumor-bearing mice Compared RLI with allogeneic lymphocyte infusion

APA, Harvard, Vancouver, ISO, and other styles

39

Maltsev, D. V. "THE EVALUATION OF THE INFLUENCE OF CETRILEV (LEVOCETIRIZINE) ON THE LATE PHASE OF THE ATOPIC REACTION." Medical Science of Ukraine (MSU) 14, no. 3-4 (2018): 103–7. http://dx.doi.org/10.32345/2664-4738.3-4.2018.14.

Full text

Abstract:

Relevance. Previously demonstrated inhibitory effect of levocetirizine on the activity of eosinophils during the late phase of the atopic reaction, but the effect of the drug on the second component of the late phase – lymphocytes – is still not specified. Objective of the study – to evaluate the effect of levocetirizine (Cetrilev) therapy on the lymphocyte component of the late phase of atopic allergic reaction in humans. Materials and methods. A single-center, prospective, comparative clinical study was conducted. Patients of the study group (SG) (n = 31) with chronic atopic dermatitis and r

APA, Harvard, Vancouver, ISO, and other styles

40

Brait, Vanessa H., Thiruma V. Arumugam, Grant R. Drummond, and Christopher G. Sobey. "Importance of T Lymphocytes in Brain Injury, Immunodeficiency, and Recovery after Cerebral Ischemia." Journal of Cerebral Blood Flow & Metabolism 32, no. 4 (2012): 598–611. http://dx.doi.org/10.1038/jcbfm.2012.6.

Full text

Abstract:

Following an ischemic stroke, T lymphocytes become activated, infiltrate the brain, and appear to release cytokines and reactive oxygen species to contribute to early inflammation and brain injury. However, some subsets of T lymphocytes may be beneficial even in the early stages after a stroke, and recent evidence suggests that T lymphocytes can also contribute to the repair and regeneration of the brain at later stages. In the hours to days after stroke, T-lymphocyte numbers are then reduced in the blood and in secondary lymphoid organs as part of a ‘stroke-induced immunodeficiency syndrome,’

APA, Harvard, Vancouver, ISO, and other styles

41

Imaoka, S., Y. Sasaki, O. Ishikawa, et al. "Immunochemotherapy in human hepatocellular carcinoma using the streptococcal agent OK-432." Journal of Clinical Oncology 4, no. 11 (1986): 1645–51. http://dx.doi.org/10.1200/jco.1986.4.11.1645.

Full text

Abstract:

Twenty-one patients with nonresectable hepatocellular carcinoma (HCC) received intraarterial infusion chemotherapy of Adriamycin (Adria Laboratories, Columbus, Ohio) via an indwelling catheter in the hepatic artery. Additional intratumoral injection therapy of OK-432 (50 KE) was administered to ten of these 21 patients. Nine of the ten patients showed a remarkable decrease in lymphocyte count on the first day after therapy. In all of the patients with a decreased lymphocyte count, computed tomograms (CTs) demonstrated evidence of necrosis associated with a rapid decrease in alpha fetoprotein (

APA, Harvard, Vancouver, ISO, and other styles

42

Olariu, Mihaela Cristina, Mihaela Adela Iancu, Mihai Hristu Olariu, et al. "Replacement Therapy with Blood Products in People Living with HIV." Tropical Medicine and Infectious Disease 9, no. 9 (2024): 213. http://dx.doi.org/10.3390/tropicalmed9090213.

Full text

Abstract:

Cytopenias or coagulation deficiencies can occur in people living with HIV (PLWH). The severity of these disorders is influenced by the low levels of CD4+ lymphocytes, viral load, and the stage of viral infection. The aim of our retrospective observational study was to determine the frequency of cytopenias and coagulation deficiencies in PLWH as well as the need for replacement therapy with blood products. We sought to determine whether there is an association between severe anemia or thrombocytopenia (requiring replacement therapy) and CD4+T lymphocyte levels. All 29 patients were critically

APA, Harvard, Vancouver, ISO, and other styles

43

Zheng, Cheng-Wan, Yun-Mo Yang, and Hui Yang. "Impact of oxaliplatin and trastuzumab combination therapy on tumor markers and T lymphocyte subsets for advanced gastric cancer." World Journal of Gastrointestinal Oncology 16, no. 9 (2024): 3905–12. http://dx.doi.org/10.4251/wjgo.v16.i9.3905.

Full text

Abstract:

BACKGROUND Advanced gastric cancer (AGC) remains a challenging malignancy with poor prognosis. The combination of oxaliplatin and trastuzumab has shown promising results in AGC treatment. This study aimed to investigate the effects of oxaliplatin and trastuzumab combination therapy on serum tumor markers and T lymphocyte subsets in patients with AGC and to explore their potential as predictive biomarkers for treatment response. AIM To investigate the impact of oxaliplatin and trastuzumab combination therapy on serum markers and T cell subsets in patients with AGC. METHODS This prospective stud

APA, Harvard, Vancouver, ISO, and other styles

44

Petrov, S. V., O. V. Boyko, and A. N. Boyko. "Experience with cladribine tablets for highly active multiple sclerosis in everyday clinical practice." Neurology, Neuropsychiatry, Psychosomatics 12, no. 1S (2020): 25–28. http://dx.doi.org/10.14412/2074-2711-2020-1s-25-28.

Full text

Abstract:

Cladribine tablets are a new drug for the immune reconstitution therapy of highly active multiple sclerosis (HAMS). After discussing the characteristics of action of the drug in clinical trials, the authors give their own experience of its use in the Moscow Multiple Sclerosis Center.Objective: to assess their own experience with cladribine tablets in the treatment of HAMS patients in everyday clinical practice.Patients and methods: In 2018–2020, a total of 14 patients with HAMS and an average exacerbation frequency of 2.42 per year (34 exacerbations) received a full cycle of cladribine therapy

APA, Harvard, Vancouver, ISO, and other styles

45

Alexander, AG, NC Barnes, AB Kay, and CJ Corrigan. "Can clinical response to cyclosporin in chronic severe asthma be predicted by an in vitro T-lymphocyte proliferation assay?" European Respiratory Journal 9, no. 7 (1996): 1421–26. https://doi.org/10.1183/13993003/erj.9.7.1421.

Full text

Abstract:

This study tests the hypothesis that the clinical response to cyclosporin therapy of patients with chronic severe asthma is related to the sensitivity of their T-lymphocytes to the antiproliferative effects of cyclosporin in vitro. In a previous study, we observed such a relationship with glucocorticoids and the same lectin-driven proliferation assay was used in the present study. Peripheral blood mononuclear cells were obtained from 33 patients participating in a cross-over trial of oral cyclosporin therapy during both cyclosporin and placebo treatment periods, and cultured in the presence of

APA, Harvard, Vancouver, ISO, and other styles

46

Yerigeri, Keval, та Ilia Buhtoiarov. "Pediatric-type follicular lymphoma in a Crohn’s disease patient receiving anti-α4β7-integrin therapy: A case report". World Journal of Gastroenterology 29, № 43 (2023): 5865–71. http://dx.doi.org/10.3748/wjg.v29.i43.5865.

Full text

Abstract:

BACKGROUND Patients with autoimmune conditions receiving immunosuppressants are at risk of non-Hodgkin lymphomas (NHL). Vedolizumab (anti-α4β7-integrin antibody), a treatment-of-choice for Crohn’s disease (CD), reduces inflammatory lymphocyte trafficking into the intestinal mucosa. This effect is believed to be confined to the colon. CASE SUMMARY We report the case of a CD patient on vedolizumab for five years who developed pediatric-type follicular lymphoma. Work-up prior to therapy revealed a reduction in circulating T-lymphocytes and their suppressed response to mitogens. Rituximab, cycloph

APA, Harvard, Vancouver, ISO, and other styles

47

Tisch, Matthias, Florίan Heimlich, Volker Daniel, Gerhard Opelz, and Heinz Maier. "Cellular immune defect caused by postsurgical radiation therapy in patients with head and neck cancer." Otolaryngology–Head and Neck Surgery 119, no. 4 (1998): 412–17. http://dx.doi.org/10.1016/s0194-5998(98)70092-0.

Full text

Abstract:

The effects of locoregional postoperative radiation therapy (60 Gy on average) on cellular immunity were investigated in 11 patients with squamocellular carcinomas of the oral cavity, pharynx, or larynx. During radiation treatment, the total lymphocyte counts, CD8+ T-lymphocyte count, and especially CD4+ T-lymphocyte count decreased significantly. The mean CD4+ T-lymphocyte counts dropped from an average of 739/μl to 183/μl ( p <0.001), and the CD4+/CD8+ quotient also decreased significantly. Not only the lymphocyte counts but also the in vitro lymphocyte stimulation responses to several mi

APA, Harvard, Vancouver, ISO, and other styles

48

Santos, Nuno C., J. Martins e Silva, Teresa Freitas, et al. "Blood Cell Membrane Fluidity and Intracellular Ca2+Changes in Antiretroviral-Naïve and -Treated HIV-1–Infected Patients." Scientific World JOURNAL 10 (2010): 350–55. http://dx.doi.org/10.1100/tsw.2010.34.

Full text

Abstract:

We previously showed that lymphocytes and erythrocytes of HIV-1–infected patients, prior to antiretroviral therapy, presented significant changes in intracellular calcium concentration ([Ca2+]int) and membrane fluidity. The present study evaluates the same parameters after response to highly active antiretroviral therapy (HAART). Blood samples were collected from patients prior to and after antiretroviral therapy, and from control subjects. Membrane fluidity and [Ca2+]intwere assessed by fluorescence spectroscopy measurements, using three different probes: TMA-DPH and DPH for membrane fluidity

APA, Harvard, Vancouver, ISO, and other styles

49

Pakola, Santeri A., James H. A. Clubb, Tatiana V. Kudling, et al. "Transient lymphocyte count decrease correlates with oncolytic adenovirus efficacy in humans: mechanistic and biomarker findings from TUNIMO phase I trial." Journal for ImmunoTherapy of Cancer 13, no. 1 (2025): e010493. https://doi.org/10.1136/jitc-2024-010493.

Full text

Abstract:

BackgroundOncolytic viruses (OVs) are promising immunotherapeutics to treat immunologically cold tumors. However, research on the mechanism of action of OVs in humans and clinically relevant biomarkers is still sparse. To induce strong T-cell responses against solid tumors, TILT-123 (Ad5/3-E2F-d24-hTNFa-IRES-hIL2, igrelimogene litadenorepvec) was developed. TILT-123 encodes two transgenes: tumor necrosis alpha (TNFa) and interleukin-2 (IL-2). TUNIMO (NCT04695327) was a phase I clinical trial using TILT-123 in patients with advanced solid tumors aiming to assess the safety, efficacy, and immuno

APA, Harvard, Vancouver, ISO, and other styles

50

Krämer, Stephanie, Eva Binder, Tanja Loof, et al. "The lymphocyte migration inhibitor FTY720 attenuates experimental hypertensive nephropathy." American Journal of Physiology-Renal Physiology 297, no. 1 (2009): F218—F227. http://dx.doi.org/10.1152/ajprenal.90617.2008.

Full text

Abstract:

The lymphocyte migration inhibitor FTY720 attenuates experimental hypertensive nephropathy. Infiltration with lymphocytes is found in both immune and nonimmune chronic kidney diseases. In a rat model of immune-initiated progressive glomerulosclerosis, selective inhibition of lymphocyte infiltration by FTY720 showed significant beneficial effects on renal fibrosis. To test whether this translates into hypertensive nephropathy (HN), the lymphocyte migration inhibitor was administered to rats following nephrectomy. Two days after surgery, male Wistar rats were allocated to the following groups: S

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!